Drug Profile
Lorundrostat - Mineralys Therapeutics
Alternative Names: MLS-101; MT-4129Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Mineralys Therapeutics; Mitsubishi Tanabe Pharma Corporation
- Class Acetamides; Amides; Antihypertensives; Benzene derivatives; Cardiovascular therapies; Cyclohexylamines; Small molecules; Triazines
- Mechanism of Action Aldosterone synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypertension
- Phase II Renal failure
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Cardiovascular-disorders(In volunteers) in Netherlands (PO)
- 21 Mar 2024 Mineralys Therapeutics plans a phase II Explore-CKD proof of concept trial for chronic kidney disease (Combination therapy, Late-stage disease) (renal failure) in second half of 2023 (PO)
- 14 Dec 2023 Phase-II clinical trials in Renal failure (Combination therapy) in USA (PO) (NCT06150924)